An interventional study of Emergency Department Peer Availability in Substance Use Disorder (SUD), sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University of British Columbia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Substance-Related Disorders with a site in Canada — 26 open to participants now, 29 under way, none of them phase 3. Substance-Related Disorders · Canada.
Among the 81 studies in Substance-Related Disorders with a site in Canada, this one is the 4th largest by planned enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2024, is one of 52 with no phase, reaches primary completion later than 23 of the 28 other live ones, and was the 76th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →26 of the 81 studies in Substance-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:
St. Joseph's Healthcare Hamilton · Sites in Canada
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–70
University Health Network, Toronto · Sites in Canada
Ages 18–85 · Healthy volunteers
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–55
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,781 is above the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 74 across the 71 interventional studies, 520 across the 9 observational. Of the 47 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 81 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 6 studies filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Substance-Related Disorders with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04812613Ottawa Hospital Research InstituteTobacco-Concurrent Addictions in At-Risk Youth in Ottawa | 2026-12-31 |
| NCT05704582Ciusss de L'Est de l'Île de MontréalRCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders | 2027-01 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT03249428Ottawa Hospital Research InstituteCytisine vs Nicotine Replacement Therapy | 2027-03 |
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 81 studies in Substance-Related Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many people with high-risk opioid use visit emergency departments (EDs), facing a high risk of death if they leave before completing care. Peer support workers (Peers) - people with lived experience of substance use - may improve patient comfort, reduce early departures, and potentially lower mortality rates. This study aims to evaluate how a hospital-implemented ED Peer program can enhance patient support, reduce barriers to care, and provide harm-reduction resources in a person-centred and trauma-informed manner. The study will assess whether Peer availability and direct Peer-patient interactions are associated with improved ED care outcomes, including reduced leaving before treatment completion, as well as subsequent healthcare utilization, overdose, mortality, and other relevant patient outcomes.
The study was initially designed as a feasibility evaluation of the ED Peer program and of the use of a randomized shift schedule to assign Peer availability. As program implementation progressed and staffing stabilized, the evaluation framework was refined to examine both the effect of Peer availability and outcomes associated with direct Peer-patient interaction.
From 23 November 2024 through 16 October 2025, Peer availability was assigned according to an a priori randomized shift schedule developed in collaboration with human resources and ED operational leadership. Following achievement of full Peer staffing, the program transitioned to routine clinical operation.
The study has two main analytic objectives: 1) during the shift-randomization period, investigators will compare outcomes between shifts with and without scheduled Peer availability among patients presenting with substance use-related concerns; 2) investigators will evaluate outcomes associated with direct Peer-patient interaction by comparing patients who interacted with a Peer with comparable patients who did not interact with a Peer.
The primary outcome is leaving before treatment completion (LBTC). Additional outcomes will include measures of ED care, subsequent healthcare utilization, substance use treatment, overdose, mortality, and other relevant clinical and health-service outcomes.
Investigators will request routinely collected records for Vancouver General Hospital ED visits during the study period. Records of eligible ED patients presenting during the study period will be linked to provincial administrative data to evaluate outcomes. Data sources will include the National Ambulatory Care Reporting System (NACRS), Discharge Abstract Database (DAD), Vital Statistics, PharmaNet, Medical Services Plan (MSP), and the Central Demographics File. Population Data BC and Health Data Platform BC will support secure data linkage, and additional relevant datasets may be explored where useful to the study objectives.
These data will support cohort definition, construction of comparison groups, development of propensity scores, sensitivity analyses, and evaluation of outcomes including receipt of ED treatments and referrals, ED revisits, hospitalizations, overdose, opioid agonist therapies and other addiction treatments, mortality, and other relevant health-service outcomes.
Investigators will also obtain records of security-related events occurring during ED visits over the study period. These data will be used to examine whether Peer availability is associated with differences in events such as need for de-escalation or other security involvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Investigators will evaluate the Peer Support intervention using two analytical approaches: 1. Primary Analysis (Intention-to-Treat): Peer Available Shift Patients who presented to the emergency department (ED) with substance use-related complaints during shifts when a Peer support worker was scheduled to be available, according to an a priori randomized schedule. Patients may or may not have directly interacted with a Peer during their ED visit. All eligible patients will be analyzed according to their randomized shift assignment, regardless of whether a direct Peer-patient interaction occurred. 2. Secondary Analysis: Interacted With Peer Patients who presented to the ED with substance use-related concerns and directly interacted with a Peer support worker during their ED visit. Peer activities may have included harm reduction support, provision of naloxone and sterile drug use supplies, linkage to substance use treatment, and connections to follow-up care and community resources.
Behavioral: Emergency Department Peer Availability
Investigators will define the comparison group using two approaches: 1. Primary Analysis (Intention-to-Treat): No Peer Available Shift Patients presenting to the ED with substance use-related complaints during shifts randomized to no Peer availability. 2. Secondary Analysis: Did Not Interact With Peer Patients presenting with similar substance use-related complaints who did not directly interact with a Peer. Investigators will use propensity score weighting to improve comparability with patients who received Peer support. The model will include relevant covariates (e.g., age, sex, area-level deprivation, prior substance use-related ED visits and hospitalizations, and prescriptions for substance dependence medications recorded in PharmaNet during the previous 12 months).
During intervention shifts, Peer support workers were scheduled to be available in the emergency department to provide support to patients with substance use-related concerns. Peer support workers offered services tailored to individual patients' needs, including referrals to clinical and social support services (e.g., social work, addictions specialists, Indigenous patient navigators, and community-based addiction services), provision of resources (e.g., blankets, food, naloxone kits, sterile drug use supplies, and information brochures), emotional support, and communication support between patients and healthcare providers regarding patients' conditions and ED care. The primary analysis will evaluate the effect of randomized Peer availability using an intention-to-treat approach. The secondary analysis will evaluate outcomes associated with actual Peer-patient interactions by comparing patients who received Peer support with comparable patients who did not.
Leaving Before Treatment Completion (LBTC)
Investigators will measure LBTC among ED patients with substance use-related complaints (e.g., substance withdrawal, misuse/intoxication, overdose, and localized swelling/redness). Investigators will evaluate LBTC using two approaches: 1. Primary Analysis (Intention-to-Treat): Peer vs. No Peer Shifts Investigators will classify eligible ED visits based on the randomized Peer schedule. For each shift, investigators will calculate the percentage of eligible visits resulting in LBTC. Linear regression will be used to compare LBTC percentages between Peer and No Peer shifts, regardless of actual Peer interaction. 2. Secondary Analysis: Peer Interaction vs. No Peer Interaction Investigators will use propensity score weighting to improve comparability between patients who interacted with a Peer and those who did not. Mixed-effects logistic regression will be used to compare LBTC probabilities between groups, accounting for clustering by shift and adjusting for relevant covariates.
Time frame: From enrollment through 12 months of follow-up
Distribution of randomized Peer shifts by day of week (feasibility outcome)
Assessed by examining the distribution of scheduled Peer shifts across each day of the week over the 48-week randomized schedule period. The schedule was developed in collaboration with human resources and ED operational leadership and approved as meeting hospital employee policy. The randomization approach used block-based scheduling with built-in constraints (e.g., mandatory weekends off). This outcome evaluates whether the resulting schedule achieved a balanced weekday/weekend distribution. Unit of Measure: Number and percentage of Peer shifts scheduled per day of the week
Time frame: From study initiation to achievement of full Peer staffing, approximately one year
ED-based substance use and harm reduction interventions
Secondary outcomes will include receipt of naloxone kits, opioid agonist therapy doses, and withdrawal treatments during the ED visit. Investigators will compare counts of these outcomes between intervention (Peer) and control (no Peer) groups using multivariable count regression. Investigators will assess clustering of outcomes by shift and adjust for the same covariates included in the primary analysis.
Time frame: Baseline
30-day health care utilization and clinical events (e.g., drug poisoning, mortality)
Exploratory outcomes will include ED visits, hospitalizations, drug poisoning, and mortality within 30 days following the index ED visit. Investigators will analyze counts of these events using multivariable count regression, with the log-transformed length of follow-up included as an offset term where applicable, and will conduct time-to-event analyses using Cox regression. Investigators will assess clustering of outcomes by shift and adjust for the same covariates included in the primary analysis.
Time frame: From enrollment through 30 days of follow-up from ED visit
Security-related events during ED visits
Investigators will obtain records of security-related events occurring during ED visits over the study period from the ED security event database. Investigators will assess whether Peer availability was associated with differences in the frequency and type of security-related events, including escalation events and incidents requiring security involvement.
Time frame: Baseline
Thematic summary of Indigenous patients' experiences with the Peer program
Indigenous patient perspectives on the Peer program will be collected through surveys, culturally grounded storytelling and sharing circles. Sessions will be guided by open-ended questions to explore perceived safety, support, and emotional impact of Peer involvement in the emergency department. Transcripts will be analyzed using Indigenous-informed thematic analysis to identify key insights and priorities for culturally safe care. Unit of Measure: Themes and narratives identified through qualitative analysis
Time frame: Within 6 months after the patient's ED visit involving Peer interaction
Thematic summary of healthcare providers' perceptions of the Peer program assessed through focus groups
Acceptability of the Peer program among healthcare providers will be evaluated using semi-structured focus groups conducted periodically post-implementation. Discussions will explore perceived value, observed patient impact, integration into ED workflows, challenges, and suggestions for improvement. Audio recordings will be transcribed and analyzed using thematic content analysis to identify recurring patterns and representative quotes. Unit of Measure: Thematic categories identified through qualitative analysis
Time frame: From 12-24 months after Peer program implementation
Thematic summary of PWLLE perceptions and experiences of the Peer program assessed through focus groups
Perspectives of people with lived and living experience (PWLLE) on the Peer program will be evaluated using semi-structured focus groups. Discussions will explore participants' perceptions of the value and accessibility of Peer support, experiences of substance use-related care in the ED, perceived impacts of the Peer program, barriers and gaps in care, and suggestions for improving Peer support and program delivery. Audio recordings will be transcribed and analyzed using thematic content analysis to identify recurring themes and representative quotes. Unit of Measure: Thematic categories identified through qualitative analysis
Time frame: From 12-24 months after Peer program implementation
Acceptability of the Peer program evaluated through periodic surveys
Acceptability and implementation of the Peer program will be assessed through periodic surveys administered to Peers, patients accessing Peer services, members of the ED buprenorphine/naloxone team, and multidisciplinary healthcare providers. Surveys will assess experiences with the Peer program, including perceived value, respect, ease of communication, clarity of information, comfort, confidentiality, teamwork, integration into ED workflows, and perceived facilitators and barriers to implementation.
Time frame: From 12-24 months after Peer program implementation
Plan to share: No — There is no plan to make individual participant data available to other researchers
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Mar 2028, 40 months after the start.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 40 months is above that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Sep 2027 → Mar 2028 and completion Dec 2027 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →